CN102333867B - C1orf59肽及包含它的疫苗 - Google Patents

C1orf59肽及包含它的疫苗 Download PDF

Info

Publication number
CN102333867B
CN102333867B CN200980157412.3A CN200980157412A CN102333867B CN 102333867 B CN102333867 B CN 102333867B CN 200980157412 A CN200980157412 A CN 200980157412A CN 102333867 B CN102333867 B CN 102333867B
Authority
CN
China
Prior art keywords
c1orf59
peptide
cancer
peptides
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980157412.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN102333867A (zh
Inventor
角田卓也
大泽龙司
吉村祥子
渡边朝久
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of CN102333867A publication Critical patent/CN102333867A/zh
Application granted granted Critical
Publication of CN102333867B publication Critical patent/CN102333867B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
CN200980157412.3A 2008-12-24 2009-12-17 C1orf59肽及包含它的疫苗 Expired - Fee Related CN102333867B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2008-327358 2008-12-24
JP2008327358 2008-12-24
US14591209P 2009-01-20 2009-01-20
US61/145,912 2009-01-20
PCT/JP2009/006944 WO2010073551A1 (en) 2008-12-24 2009-12-17 C1orf59 peptides and vaccines including the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201410336021.0A Division CN104193816A (zh) 2008-12-24 2009-12-17 C1orf59肽及包含它的疫苗

Publications (2)

Publication Number Publication Date
CN102333867A CN102333867A (zh) 2012-01-25
CN102333867B true CN102333867B (zh) 2015-01-14

Family

ID=42287204

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200980157412.3A Expired - Fee Related CN102333867B (zh) 2008-12-24 2009-12-17 C1orf59肽及包含它的疫苗
CN201410336021.0A Pending CN104193816A (zh) 2008-12-24 2009-12-17 C1orf59肽及包含它的疫苗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201410336021.0A Pending CN104193816A (zh) 2008-12-24 2009-12-17 C1orf59肽及包含它的疫苗

Country Status (14)

Country Link
US (2) US8735361B2 (enExample)
EP (1) EP2382314A4 (enExample)
JP (1) JP5728716B2 (enExample)
KR (1) KR20110117112A (enExample)
CN (2) CN102333867B (enExample)
AU (1) AU2009332389A1 (enExample)
BR (1) BRPI0923402A2 (enExample)
CA (1) CA2747686A1 (enExample)
IL (1) IL213318A0 (enExample)
MX (1) MX2011006755A (enExample)
RU (1) RU2011130796A (enExample)
SG (1) SG172374A1 (enExample)
TW (1) TW201030018A (enExample)
WO (1) WO2010073551A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2382314A4 (en) 2008-12-24 2013-03-06 Oncotherapy Science Inc C1ORF59 PEPTIDES AND VACCINES COMPRISING THEM
WO2011161960A1 (en) * 2010-06-23 2011-12-29 Oncotherapy Science, Inc. C1orf59 for target genes of cancer therapy and diagnosis
KR20140138900A (ko) 2012-03-09 2014-12-04 온코세라피 사이언스 가부시키가이샤 펩티드를 포함한 의약 조성물
RU2663350C2 (ru) 2012-09-11 2018-08-03 Онкотерапи Сайенс, Инк. Пептиды ube2t и содержащие их вакцины

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997044667A2 (fr) * 1996-05-21 1997-11-27 Institut Pasteur Methodes d'utilisation de complexes peptide/complexe majeur d'histocompatibilite pour obtenir ou purifier des cellules t antigene-specifiques et pour stimuler des cellules t
CN1379041A (zh) * 2001-04-03 2002-11-13 宝酒造株式会社 细胞毒性t淋巴细胞
CN1849395A (zh) * 2003-07-11 2006-10-18 大日本住友制药株式会社 来源于Livin的HLA－A24结合性癌抗原肽
CN101139392A (zh) * 2002-09-12 2008-03-12 肿瘤疗法科学股份有限公司 Kdr肽和包括该肽的疫苗
CN101151280A (zh) * 2005-02-08 2008-03-26 昆士兰医学研究学院委员会 免疫原性分子
WO2008081581A1 (en) * 2007-01-03 2008-07-10 Oncotherapy Science, Inc. Foxp3 peptide vaccine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
DE60238864D1 (de) 2001-11-07 2011-02-17 Mankind Corp Für epitope von antigenen kodierende expressionsvektoren und verfahren zu deren konzeption
TWI324608B (en) 2003-02-28 2010-05-11 Oncotherapy Science Inc Genes and polypeptides relating to human colorectal cancers
JP4628208B2 (ja) 2004-08-10 2011-02-09 オンコセラピー・サイエンス株式会社 Ｃｘａｄｒｌ１またはｇｃｕｄ１タンパク質を発現する胃癌または結腸直腸癌の治療のためのペプチドワクチン
ES2459492T3 (es) 2005-02-25 2014-05-09 Oncotherapy Science, Inc. Vacunas de péptidos para cánceres de pulmón que expresan polipéptidos TTK, URLC10 o KOC1
CN1948342B (zh) * 2005-10-14 2010-12-29 中国人民解放军第二军医大学 一种新的候选癌基因hRabJ来源的HLA-A2限制性表位多肽及其应用
CA2676090A1 (en) * 2007-02-06 2008-10-02 Genizon Biosciences Inc. Genemap of the human genes associated with adhd
TWI615403B (zh) * 2007-02-21 2018-02-21 腫瘤療法 科學股份有限公司 表現腫瘤相關抗原之癌症的胜肽疫苗
EP2382314A4 (en) 2008-12-24 2013-03-06 Oncotherapy Science Inc C1ORF59 PEPTIDES AND VACCINES COMPRISING THEM

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997044667A2 (fr) * 1996-05-21 1997-11-27 Institut Pasteur Methodes d'utilisation de complexes peptide/complexe majeur d'histocompatibilite pour obtenir ou purifier des cellules t antigene-specifiques et pour stimuler des cellules t
CN1379041A (zh) * 2001-04-03 2002-11-13 宝酒造株式会社 细胞毒性t淋巴细胞
CN101139392A (zh) * 2002-09-12 2008-03-12 肿瘤疗法科学股份有限公司 Kdr肽和包括该肽的疫苗
CN1849395A (zh) * 2003-07-11 2006-10-18 大日本住友制药株式会社 来源于Livin的HLA－A24结合性癌抗原肽
CN101151280A (zh) * 2005-02-08 2008-03-26 昆士兰医学研究学院委员会 免疫原性分子
WO2008081581A1 (en) * 2007-01-03 2008-07-10 Oncotherapy Science, Inc. Foxp3 peptide vaccine

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Chromosome 1 open reading frame 59 [Homo;Strausberg,R.L. et al.;《Genbank》;20060615;1-4页 *
NCBI GDS1761;Ross DT et al.;《NCBI DATASET BROWSER》;20041124;全文 *
NCBI GDS2902;Irigoyen M et al.;《NCBI DATASET BROWSER》;20070823;全文 *
NCBI GDS823;Mecham BH et al.;《NCBI DATASET BROWSER》;20040412;全文 *

Also Published As

Publication number Publication date
IL213318A0 (en) 2011-07-31
CA2747686A1 (en) 2010-07-01
JP5728716B2 (ja) 2015-06-03
US20120003253A1 (en) 2012-01-05
JP2012513742A (ja) 2012-06-21
RU2011130796A (ru) 2013-01-27
EP2382314A1 (en) 2011-11-02
US20140199335A1 (en) 2014-07-17
MX2011006755A (es) 2011-07-20
AU2009332389A1 (en) 2011-07-14
WO2010073551A1 (en) 2010-07-01
TW201030018A (en) 2010-08-16
CN104193816A (zh) 2014-12-10
KR20110117112A (ko) 2011-10-26
SG172374A1 (en) 2011-07-28
EP2382314A4 (en) 2013-03-06
CN102333867A (zh) 2012-01-25
BRPI0923402A2 (pt) 2015-08-04
US8735361B2 (en) 2014-05-27

Similar Documents

Publication Publication Date Title
CN102405285B (zh) Foxm1肽及包含它的疫苗
CN102119171A (zh) Cdca1表位肽及包含它的疫苗
CN102171340B (zh) Melk表位肽及包含它的疫苗
CN102333867B (zh) C1orf59肽及包含它的疫苗
US9745343B2 (en) Method of inducing an immune response by administering WDRPUH epitope peptides
WO2010070877A1 (en) Elovl7 epitope peptides and vaccines containing the same
AU2010216980B2 (en) FOXM1 peptides and vaccines containing the same
HK1240953A1 (en) Wdrpuh epitope peptides and vaccines containing the same
HK1165460B (en) Foxm1 peptides and vaccines containing the same
HK1165460A (en) Foxm1 peptides and vaccines containing the same

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150114

Termination date: 20151217

EXPY Termination of patent right or utility model